Literature DB >> 9033355

Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response.

E Allaire1, A W Clowes.   

Abstract

Arteries and veins respond to injury by a healing process that includes the development of a neointima. This response to injury is implicated as the primary cause of failure after arterial reconstruction. Because it is an integrator and transmitter of blood flow variations, inflammation, and growth stimuli, the endothelium is a potent regulator of long-term arterial wall mass changes. The contribution of the endothelium to intimal development depends on the type of arterial conduit. In arteries, the growth of the intima stops when the endothelium has regrown. In synthetic grafts, the endothelium stabilizes intimal growth. Hence, the mere presence of endothelial cells can influence intimal changes in arterial conduits. Understanding endothelial biology should help us define methods to prevent cell proliferation, extracellular matrix accumulation, intimal hyperplasia, and vessel narrowing.

Entities:  

Mesh:

Year:  1997        PMID: 9033355     DOI: 10.1016/s0003-4975(96)01045-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  29 in total

Review 1.  The endothelium: physiological functions and role in microcirculatory failure during severe sepsis.

Authors:  H Ait-Oufella; E Maury; S Lehoux; B Guidet; G Offenstadt
Journal:  Intensive Care Med       Date:  2010-05-05       Impact factor: 17.440

2.  FRNK overexpression limits the depth and frequency of vascular smooth muscle cell invasion in a three-dimensional fibrin matrix.

Authors:  L P Brewster; A A Ucuzian; E M Brey; M Liwanag; A M Samarel; H P Greisler
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Long-term viability of coronary artery smooth muscle cells on poly(L-lactide-co-epsilon-caprolactone) nanofibrous scaffold indicates its potential for blood vessel tissue engineering.

Authors:  Yixiang Dong; Thomas Yong; Susan Liao; Casey K Chan; S Ramakrishna
Journal:  J R Soc Interface       Date:  2008-09-06       Impact factor: 4.118

Review 4.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

5.  Electrospun rapamycin-eluting polyurethane fibers for vascular grafts.

Authors:  Jingjia Han; Shady Farah; Abraham J Domb; Peter I Lelkes
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

Review 6.  Current understanding of intimal hyperplasia and effect of compliance in synthetic small diameter vascular grafts.

Authors:  YeJin Jeong; Yuan Yao; Evelyn K F Yim
Journal:  Biomater Sci       Date:  2020-07-09       Impact factor: 6.843

7.  Making the cut: Innovative methods for optimizing perfusion-based migration assays.

Authors:  Andrew W Holt; William E Howard; Elizabeth T Ables; Stephanie M George; Cindy A Kukoly; Jake E Rabidou; Jake T Francisco; Angel N Chukwu; David A Tulis
Journal:  Cytometry A       Date:  2016-12-16       Impact factor: 4.355

Review 8.  Induction of vascular atrophy as a novel approach to treating restenosis. A review.

Authors:  Seung-Kee Min; Richard D Kenagy; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2007-10-22       Impact factor: 4.268

Review 9.  Role of smooth muscle cells in coronary artery bypass grafting failure.

Authors:  Kerry Wadey; Joshua Lopes; Michelle Bendeck; Sarah George
Journal:  Cardiovasc Res       Date:  2018-03-15       Impact factor: 10.787

Review 10.  Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures.

Authors:  Timothy C Boire; Daniel A Balikov; Yunki Lee; Christy M Guth; Joyce Cheung-Flynn; Hak-Joon Sung
Journal:  Macromol Rapid Commun       Date:  2016-09-27       Impact factor: 5.734

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.